Radiopharmaceutical Therapy

Radiopharmaceutical Therapy is the treatment of cancer with radioactive pharmaceuticals. Zevalin is a monoclonal antibody with a radioactive isotope (Yttrium-90) attached. As part of the Zevalin treatment regiment this is the first radioimmunotherapy medication approved by the FDA to treat a non-Hodgkin's lymphoma patient. When injected into a patient with B-cell non-Hodgkin's lymphoma, Zevalin circulates through the body until it locates and binds with a protein found on the surface of specific cells. It then delivers radiation to specific and neighboring cells to damage the targeted malignant cells. Zevalin therapeutic regimen is delivered on an outpatient basis traditionally over eight days. The treatment regimen includes various other procedures in conjunction with a medical oncologist and diagnostic imaging lab.

 

 

Bookmark and Share